Helixmith（A084990）株式概要株式会社ヘリックスミスは、生物学的および天然栄養補助食品を開発している。 詳細A084990 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去5年間の収益は年間28.9%増加しました。 リスク分析KR市場と比較した過去 3 か月間の株価の変動意味のある収益がありません ( ₩2B )すべてのリスクチェックを見るA084990 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩6.37k3.0k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-114b5b2016201920222025202620282031Revenue ₩3.0bEarnings ₩546.7mAdvancedSet Fair ValueView all narrativesHelixmith Co., Ltd 競合他社Anterogen.Co.LtdSymbol: KOSDAQ:A065660Market cap: ₩272.2bHansBiomedSymbol: KOSDAQ:A042520Market cap: ₩415.0bHEM PharmaSymbol: KOSDAQ:A376270Market cap: ₩355.2bY-BiologicsSymbol: KOSDAQ:A338840Market cap: ₩256.4b価格と性能株価の高値、安値、推移の概要Helixmith過去の株価現在の株価₩6,370.0052週高値₩9,960.0052週安値₩2,770.00ベータ0.641ヶ月の変化-26.10%3ヶ月変化-0.62%1年変化91.58%3年間の変化-24.17%5年間の変化-77.29%IPOからの変化-57.07%最新ニュースNew Risk • Apr 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (₩2.6b revenue, or US$1.7m).分析記事 • Mar 27We're Not Very Worried About Helixmith's (KOSDAQ:084990) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Helixmith ( KOSDAQ:084990...お知らせ • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South KoreaNew Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Revenue is less than US$5m (₩5.0b revenue, or US$3.6m).New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (26% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change).New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.7m).最新情報をもっと見るRecent updatesNew Risk • Apr 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (₩2.6b revenue, or US$1.7m).分析記事 • Mar 27We're Not Very Worried About Helixmith's (KOSDAQ:084990) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Helixmith ( KOSDAQ:084990...お知らせ • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South KoreaNew Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Revenue is less than US$5m (₩5.0b revenue, or US$3.6m).New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (26% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change).New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.7m).分析記事 • Jul 14We Think Helixmith (KOSDAQ:084990) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Mar 18Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South KoreaNew Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (₩127.3b market cap, or US$89.5m).New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.0b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (₩3.2b revenue, or US$2.3m). Market cap is less than US$100m (₩140.0b market cap, or US$99.9m).分析記事 • Oct 18Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Apr 26Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in fundingOn April 25, 2024, Helixmith Co., Ltd closed the transaction.お知らせ • Feb 06Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in fundingHelixmith Co., Ltd announced a private placement of 936,066 common shares at a price of KRW 3,610 per share for the gross proceeds of KRW 3,379,198,260 on February 5, 2024. The transaction has been approved by the shareholders of the company and is expected to close on April 25, 2024. The transaction will include participation from new investor, Woori Bank Magongnaru Station Branch.New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Revenue is less than US$5m (₩4.4b revenue, or US$3.4m).お知らせ • Feb 09Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc.Helixmith Co., Ltd announced a private placement of 936,066 common shares of par value KRW 500 to be issued at an issue price of KRW 10,683 per share for proceeds of KRW 9,999,993,078 on February 7, 2023. The transaction will include participation from returning investor CANARIABIO M Inc. The shares are to be issued pursuant to third party allotment method. The transaction is expected to close on February 15, 2023. The transaction has been approved by the board of directors. The securities will be subject to a hold period of one year.Price Target Changed • Nov 29Price target decreased to ₩19,900Down from ₩29,600, the current price target is provided by 1 analyst. New target price is 51% above last closing price of ₩13,150. Stock is down 41% over the past year. The company posted a net loss per share of ₩1,753 last year.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Sep 19Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)お知らせ • Sep 07Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)Helixmith announced topline results from a Phase 2A study in individuals with ALS (Amyotrophic Lateral Sclerosis). ALS is a fatal neurodegenerative disorder of upper and lower motor neurons that causes progressive paralysis and eventual death due to respiratory failure. This Phase 2A was a double-blind placebo controlled multi-center study involving 5 sites (4 in the US and 1 in Korea) and 18 subjects randomized to a 2:1 ratio of Engensis to placebo. In this Phase 2A study, three treatments of Engensis, a plasmid DNA encoding human HGF, or placebo were injected in the upper and lower limbs on months 0, 2 and 4. One treatment consisted of two cycles of injections, on 2-week intervals, of 64 mg of Engensis or placebo in total. Therefore, a total of 192 mg of Engensis was given to each subject over a 4-month period. In addition, there was a follow-up period of 6 months after the first injection on Day 0. The results of the study demonstrated that Engensis was safe and well tolerated at this dosing regimen. There was no difference in the frequency of TEAEs (83% for each group) between the Engensis and the placebo groups. One TEAE, bronchitis, was reported in the Engensis group but was determined to not be related to the study drug. Injection site reactions were reported by 50% of the Engensis group and by 66.7% of the placebo group. Most of the injection site reactions were Grade 1 or 2 and resolved within a short time, and none of the participants in the study discontinued due to the number of injections. These data suggest that high dose, repeated treatments of Engensis, were safe and well tolerated, providing a great deal of flexibility in designing dosing schemes for future clinical studies. Given the primary endpoint of this study was to test safety and tolerability, efficacy was measured only as an exploratory parameter. ALSFRS-R scores, muscle functions using handheld dynamometry, and ALSAQ-40 were among the measurements collected. Since the study size was small and 4 subjects dropped out early, the company were unable to compare efficacy between the Engensis and placebo groups. An important component of this study was the collection of biopsy samples from the participants' injections sites. Engensis is an intramuscularly delivered gene therapy. The bulk of the data collected to date, showing effects of HGF expressed from Engensis, has been from animal models. Data collected from clinical trials has been limited thus far. Thanks to dedicated clinical trial participants, muscle biopsy samples were collected during the course of the trial and will be subjected to histological and molecular biological analyses using RNA-Seq. Helixmith greatly appreciates the generous and eager participation of the ALS patients. Data from these results are expected to provide valuable information on the understanding of the mechanisms of actions of Engensis, and its effects on the expression of human genes, which will greatly help in the development of innovative medicines based on HGF/c-Met signaling. Helixmith will continue the analysis of the Phase 2A data upon the receipt of the full report and plan to present results at a future conference and determine next steps for Engensis in ALS at that time.お知らせ • Aug 04Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19Helixmith announced topline results from the double-blind placebo controlled multicenter study for TADIOS involving one hundred subjects infected with COVID-19. This study was conducted in India in compliance with AYUSH guidelines. TADIOS is Helixmith's proprietary botanical formulation composed of three plants, which has been developed for the treatment of respiratory disease caused by viruses, microdust, and such. The primary goal of this study was to evaluate safety and tolerability of TADIOS, as well as its effects on efficacy parameters, which included biomarkers and clinical symptoms. Subjects diagnosed with COVID-19 infection, showing mild to moderate symptoms, were enrolled according to the clinical management guidelines of the Government of India. Subjects were randomized to TADIOS and placebo with a 1:1 ratio in which fifty patients were assigned in each group. TADIOS and placebo were administered in addition to the standard of care in a double-blinded manner. Efficacy parameters were measured after the 10-day treatment maximum per COVID-19 treatment guideline of India. Safety was assessed at 14-day follow up after treatment was completed. TADIOS was determined to be safe and well tolerated. The TADIOS treated group did not show any difference in adverse events compared to the placebo group, confirming its potential to be developed as a safe botanical treatment for COVID-19 treatment. In terms of efficacy, IL-1RA biomarker showed a statistically significant difference and improvement was demonstrated in one of the fatigue-related questionnaires. IL-1RA levels were higher by more than 3-fold in both groups, but the TADIOS treatment group showed a lower level at 2 weeks after the end of administration, compared to the placebo group (p<0.05). It has been reported that IL-1RA is maintained at elevated levels in blood during COVID-19 infection, and its level has a close correlation with the severity and mortality of infection. While known to regulate excessive inflammation, it is also present at elevated levels in a variety of pathologic conditions, such as obesity and rheumatoid arthritis, as well as at the severe stage of COVID-19 infection. Therefore, reduction of IR-1RA by taking TADIOS suggests its possibility of preventing or inhibiting the progression of symptoms caused by COVID-19 infection to severe illness. Among the six biomarkers measured, serum levels of CRP, ferritin, TNF-a and the level of hemoglobin in whole blood were all within the normal range in both groups. and no difference was shown between the two groups. TADIOS showed some improvement in fatigue, a common symptom in individuals with COVID-19 infections. In one of the questionnaires testing "I am easily fatigued," TADIOS-administered subjects showed statistically significant improvement vs placebo group, two weeks after treatment (p<0.05). Helixmith is planning to present full data at either an academic conference or in a journal publication upon the completion of the analysis.Reported Earnings • May 26First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021)First quarter 2022 results: ₩335 loss per share (down from ₩92.65 profit in 1Q 2021). Net loss: ₩12.6b (down ₩15.3b from profit in 1Q 2021). Over the next year, revenue is expected to shrink by 16% compared to a 25% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 28Price target increased to ₩29,182Up from ₩26,529, the current price target is provided by 1 analyst. New target price is 44% above last closing price of ₩20,200. Stock is down 27% over the past year. The company posted a net loss per share of ₩1,753 last year.Price Target Changed • Apr 27Price target decreased to ₩26,529Down from ₩29,182, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₩20,150. Stock is down 29% over the past year. The company posted a net loss per share of ₩1,753 last year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Price Target Changed • Dec 29Price target decreased to ₩26,529Down from ₩32,100, the current price target is provided by 1 analyst. New target price is 19% above last closing price of ₩22,350. Stock is down 26% over the past year. The company posted a net loss per share of ₩3,094 last year.お知らせ • Dec 02Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOSHelixmith Co. Ltd. has announced that 50 subjects have been enrolled in its double-blind placebo controlled COVID-19 clinical trial involving 100 subjects. The investigational product is called TADIOS, which is a proprietary botanical treatment. The clinical trial is being conducted in India in accordance with the regulations of the Ministry of AYUSH, India's traditional medicine regulatory body. India has a high rate of COVID-19 infection and unmet medical need. The ongoing TADIOS clinical trial is being conducted in four trial sites. The trial is targeting patients diagnosed with COVID-19 who have mild to moderate clinical symptoms. Patients are being randomized 1:1, 50 subjects to the TADIOS group and 50 to the placebo group. TADIOS is being orally administered as an adjuvant to the COVID-19 standard treatment regimen under double-blinded conditions, and its efficacy and safety are assessed at 10 days and 14 days after administration. Various biochemical indicators, such as TNF-alpha, CRP, IL-6, IL-1Ra, Hb, and ferritin, are being measured at 10 days post administration or at the time of discharge, if earlier than 10 days. Anti-inflammatory and anti-oxidative activities are also being assessed. Clinical symptom improvement is determined using an 8-point sequence scale designed by the WHO. Quality of life, fatigue, and hospitalization periods are also evaluated. In pre-clinical studies, TADIOS (HX110) has shown to significantly inhibit lung damage in an acute lung injury mouse model. The therapeutic effects appeared to result from the control of excessive production of inflammatory and oxidative molecules such as TNF-a, IL-6, IL-1ß and ROS. The potential molecular mechanism underlying TADIOS' anti-inflammatory and anti-oxidative activities is its control of the Nrf2-HO-1 pathway. Thus, TADIOS appears to prevent or inhibit disease progression upon viral infection through a reduction of inflammatory and oxidative response. The results of these studies were published in the Journal of Ethnopharmacology.Price Target Changed • Apr 16Price target decreased to ₩33,000Down from ₩48,697, the current price target is provided by 1 analyst. New target price is 29% above last closing price of ₩25,500. Stock is down 62% over the past year.Is New 90 Day High Low • Feb 24New 90-day low: ₩24,550The company is down 16% from its price of ₩29,200 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.分析記事 • Feb 19Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize with...お知らせ • Jan 23Helixmith Co., Ltd announced that it has received KRW 20 billion in fundingOn January 22, 2021, Helixmith Co., Ltd (KOSDAQ:A084990) closed the transaction.お知らせ • Jan 22Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in fundingHelixmith Co., Ltd (KOSDAQ:A084990) announced a private placement of 4th series unregistered non-guaranteed private convertible bonds for gross proceeds of KRW 20,000,000,000 on January 20, 2021. The transaction will include participation from new investor, Japan-made New Bio Fund. The bond is issued at 0% coupon rate and will mature on January 22, 2026. The bonds are 100% converted into 657,527 common shares representing 1.92% stake at a fixed conversion price of KRW 30,417 per share. The conversion period is from January 22, 2022 to December 22, 2025. The transaction has been approved by the board of directors of the company. The subscription date is January 20, 2021 and payment date is January 22, 2021.お知らせ • Dec 23Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion.Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,500,000 Price\Range: KRW 21500 Discount Per Security: KRW 322.5 Transaction Features: Rights OfferingIs New 90 Day High Low • Oct 16New 90-day low: ₩30,750The company is down 48% from its price of ₩58,800 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.お知らせ • Oct 06Helixmith to Be Deleted from Other OTCHelixmith Co., Ltd’s Ordinary Shares will be deleted from Other OTC effective September 29, 2020. The deletion is due to Inactive Security.Is New 90 Day High Low • Sep 18New 90-day low: ₩41,800The company is down 35% from its price of ₩64,500 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.株主還元A084990KR BiotechsKR 市場7D-15.5%-2.0%6.7%1Y91.6%25.9%195.0%株主還元を見る業界別リターン: A084990過去 1 年間で25.9 % の収益を上げたKR Biotechs業界を上回りました。リターン対市場: A084990は、過去 1 年間で195 % のリターンを上げたKR市場を下回りました。価格変動Is A084990's price volatile compared to industry and market?A084990 volatilityA084990 Average Weekly Movement15.3%Biotechs Industry Average Movement11.5%Market Average Movement9.5%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%安定した株価: A084990の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A084990の weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてKRの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト199638Song-Sun Changwww.helixmith.com株式会社ヘリックスミスは生物学的製剤と天然栄養補助食品を開発している。同社は、変形性関節症のためのLAYLA Tab、過敏症改善のためのAllexとAllex i、記憶力改善のためのMnemosyneを提供している。同社の主要遺伝子治療製品はエンジェンシス（VM202）で、糖尿病性末梢神経障害と糖尿病性足潰瘍を対象とした第III相臨床試験、筋萎縮性側索硬化症（ALS）と跛行を対象とした第II相臨床試験、シャルコー・マリー・トゥース病と冠動脈疾患を対象とした第I相臨床試験が進行中である。また、慢性腎臓病治療薬としてc-METを検出・活性化する抗体VM507、末梢神経障害治療薬NM101、ALS治療薬NM301、NM302、炎症性腸疾患治療薬HX204、前立腺疾患治療薬HX109、呼吸器疾患治療薬HX110、更年期障害治療薬HX112も開発している。同社は以前はViroMed Co, Ltd.として知られていたが、2019年4月にHelixmith Co, Ltd.に社名を変更した。Helixmith Co,Ltdは1996年に設立され、韓国のソウルに本社を置いている。もっと見るHelixmith Co., Ltd 基礎のまとめHelixmith の収益と売上を時価総額と比較するとどうか。A084990 基礎統計学時価総額₩293.32b収益（TTM）-₩305.51m売上高(TTM)₩2.22b132.0xP/Sレシオ-960.1xPER（株価収益率A084990 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A084990 損益計算書（TTM）収益₩2.22b売上原価₩1.25b売上総利益₩974.25mその他の費用₩1.28b収益-₩305.51m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-6.63グロス・マージン43.83%純利益率-13.75%有利子負債／自己資本比率0%A084990 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/30 22:49終値2026/05/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Helixmith Co., Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Sangsoo KimGoldman SachsJaeik KimiM SecuritiesWan KuNH Investment & Securities Co., Ltd.1 その他のアナリストを表示
New Risk • Apr 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (₩2.6b revenue, or US$1.7m).
分析記事 • Mar 27We're Not Very Worried About Helixmith's (KOSDAQ:084990) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Helixmith ( KOSDAQ:084990...
お知らせ • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South Korea
New Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Revenue is less than US$5m (₩5.0b revenue, or US$3.6m).
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (26% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change).
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.7m).
New Risk • Apr 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (₩2.6b revenue, or US$1.7m).
分析記事 • Mar 27We're Not Very Worried About Helixmith's (KOSDAQ:084990) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Helixmith ( KOSDAQ:084990...
お知らせ • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South Korea
New Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Revenue is less than US$5m (₩5.0b revenue, or US$3.6m).
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (26% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change).
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.7m).
分析記事 • Jul 14We Think Helixmith (KOSDAQ:084990) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Mar 18Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Mar 13Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South Korea
New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (₩127.3b market cap, or US$89.5m).
New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.0b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (₩3.2b revenue, or US$2.3m). Market cap is less than US$100m (₩140.0b market cap, or US$99.9m).
分析記事 • Oct 18Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Apr 26Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in fundingOn April 25, 2024, Helixmith Co., Ltd closed the transaction.
お知らせ • Feb 06Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in fundingHelixmith Co., Ltd announced a private placement of 936,066 common shares at a price of KRW 3,610 per share for the gross proceeds of KRW 3,379,198,260 on February 5, 2024. The transaction has been approved by the shareholders of the company and is expected to close on April 25, 2024. The transaction will include participation from new investor, Woori Bank Magongnaru Station Branch.
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Revenue is less than US$5m (₩4.4b revenue, or US$3.4m).
お知らせ • Feb 09Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc.Helixmith Co., Ltd announced a private placement of 936,066 common shares of par value KRW 500 to be issued at an issue price of KRW 10,683 per share for proceeds of KRW 9,999,993,078 on February 7, 2023. The transaction will include participation from returning investor CANARIABIO M Inc. The shares are to be issued pursuant to third party allotment method. The transaction is expected to close on February 15, 2023. The transaction has been approved by the board of directors. The securities will be subject to a hold period of one year.
Price Target Changed • Nov 29Price target decreased to ₩19,900Down from ₩29,600, the current price target is provided by 1 analyst. New target price is 51% above last closing price of ₩13,150. Stock is down 41% over the past year. The company posted a net loss per share of ₩1,753 last year.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Sep 19Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)
お知らせ • Sep 07Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)Helixmith announced topline results from a Phase 2A study in individuals with ALS (Amyotrophic Lateral Sclerosis). ALS is a fatal neurodegenerative disorder of upper and lower motor neurons that causes progressive paralysis and eventual death due to respiratory failure. This Phase 2A was a double-blind placebo controlled multi-center study involving 5 sites (4 in the US and 1 in Korea) and 18 subjects randomized to a 2:1 ratio of Engensis to placebo. In this Phase 2A study, three treatments of Engensis, a plasmid DNA encoding human HGF, or placebo were injected in the upper and lower limbs on months 0, 2 and 4. One treatment consisted of two cycles of injections, on 2-week intervals, of 64 mg of Engensis or placebo in total. Therefore, a total of 192 mg of Engensis was given to each subject over a 4-month period. In addition, there was a follow-up period of 6 months after the first injection on Day 0. The results of the study demonstrated that Engensis was safe and well tolerated at this dosing regimen. There was no difference in the frequency of TEAEs (83% for each group) between the Engensis and the placebo groups. One TEAE, bronchitis, was reported in the Engensis group but was determined to not be related to the study drug. Injection site reactions were reported by 50% of the Engensis group and by 66.7% of the placebo group. Most of the injection site reactions were Grade 1 or 2 and resolved within a short time, and none of the participants in the study discontinued due to the number of injections. These data suggest that high dose, repeated treatments of Engensis, were safe and well tolerated, providing a great deal of flexibility in designing dosing schemes for future clinical studies. Given the primary endpoint of this study was to test safety and tolerability, efficacy was measured only as an exploratory parameter. ALSFRS-R scores, muscle functions using handheld dynamometry, and ALSAQ-40 were among the measurements collected. Since the study size was small and 4 subjects dropped out early, the company were unable to compare efficacy between the Engensis and placebo groups. An important component of this study was the collection of biopsy samples from the participants' injections sites. Engensis is an intramuscularly delivered gene therapy. The bulk of the data collected to date, showing effects of HGF expressed from Engensis, has been from animal models. Data collected from clinical trials has been limited thus far. Thanks to dedicated clinical trial participants, muscle biopsy samples were collected during the course of the trial and will be subjected to histological and molecular biological analyses using RNA-Seq. Helixmith greatly appreciates the generous and eager participation of the ALS patients. Data from these results are expected to provide valuable information on the understanding of the mechanisms of actions of Engensis, and its effects on the expression of human genes, which will greatly help in the development of innovative medicines based on HGF/c-Met signaling. Helixmith will continue the analysis of the Phase 2A data upon the receipt of the full report and plan to present results at a future conference and determine next steps for Engensis in ALS at that time.
お知らせ • Aug 04Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19Helixmith announced topline results from the double-blind placebo controlled multicenter study for TADIOS involving one hundred subjects infected with COVID-19. This study was conducted in India in compliance with AYUSH guidelines. TADIOS is Helixmith's proprietary botanical formulation composed of three plants, which has been developed for the treatment of respiratory disease caused by viruses, microdust, and such. The primary goal of this study was to evaluate safety and tolerability of TADIOS, as well as its effects on efficacy parameters, which included biomarkers and clinical symptoms. Subjects diagnosed with COVID-19 infection, showing mild to moderate symptoms, were enrolled according to the clinical management guidelines of the Government of India. Subjects were randomized to TADIOS and placebo with a 1:1 ratio in which fifty patients were assigned in each group. TADIOS and placebo were administered in addition to the standard of care in a double-blinded manner. Efficacy parameters were measured after the 10-day treatment maximum per COVID-19 treatment guideline of India. Safety was assessed at 14-day follow up after treatment was completed. TADIOS was determined to be safe and well tolerated. The TADIOS treated group did not show any difference in adverse events compared to the placebo group, confirming its potential to be developed as a safe botanical treatment for COVID-19 treatment. In terms of efficacy, IL-1RA biomarker showed a statistically significant difference and improvement was demonstrated in one of the fatigue-related questionnaires. IL-1RA levels were higher by more than 3-fold in both groups, but the TADIOS treatment group showed a lower level at 2 weeks after the end of administration, compared to the placebo group (p<0.05). It has been reported that IL-1RA is maintained at elevated levels in blood during COVID-19 infection, and its level has a close correlation with the severity and mortality of infection. While known to regulate excessive inflammation, it is also present at elevated levels in a variety of pathologic conditions, such as obesity and rheumatoid arthritis, as well as at the severe stage of COVID-19 infection. Therefore, reduction of IR-1RA by taking TADIOS suggests its possibility of preventing or inhibiting the progression of symptoms caused by COVID-19 infection to severe illness. Among the six biomarkers measured, serum levels of CRP, ferritin, TNF-a and the level of hemoglobin in whole blood were all within the normal range in both groups. and no difference was shown between the two groups. TADIOS showed some improvement in fatigue, a common symptom in individuals with COVID-19 infections. In one of the questionnaires testing "I am easily fatigued," TADIOS-administered subjects showed statistically significant improvement vs placebo group, two weeks after treatment (p<0.05). Helixmith is planning to present full data at either an academic conference or in a journal publication upon the completion of the analysis.
Reported Earnings • May 26First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021)First quarter 2022 results: ₩335 loss per share (down from ₩92.65 profit in 1Q 2021). Net loss: ₩12.6b (down ₩15.3b from profit in 1Q 2021). Over the next year, revenue is expected to shrink by 16% compared to a 25% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 28Price target increased to ₩29,182Up from ₩26,529, the current price target is provided by 1 analyst. New target price is 44% above last closing price of ₩20,200. Stock is down 27% over the past year. The company posted a net loss per share of ₩1,753 last year.
Price Target Changed • Apr 27Price target decreased to ₩26,529Down from ₩29,182, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₩20,150. Stock is down 29% over the past year. The company posted a net loss per share of ₩1,753 last year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Price Target Changed • Dec 29Price target decreased to ₩26,529Down from ₩32,100, the current price target is provided by 1 analyst. New target price is 19% above last closing price of ₩22,350. Stock is down 26% over the past year. The company posted a net loss per share of ₩3,094 last year.
お知らせ • Dec 02Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOSHelixmith Co. Ltd. has announced that 50 subjects have been enrolled in its double-blind placebo controlled COVID-19 clinical trial involving 100 subjects. The investigational product is called TADIOS, which is a proprietary botanical treatment. The clinical trial is being conducted in India in accordance with the regulations of the Ministry of AYUSH, India's traditional medicine regulatory body. India has a high rate of COVID-19 infection and unmet medical need. The ongoing TADIOS clinical trial is being conducted in four trial sites. The trial is targeting patients diagnosed with COVID-19 who have mild to moderate clinical symptoms. Patients are being randomized 1:1, 50 subjects to the TADIOS group and 50 to the placebo group. TADIOS is being orally administered as an adjuvant to the COVID-19 standard treatment regimen under double-blinded conditions, and its efficacy and safety are assessed at 10 days and 14 days after administration. Various biochemical indicators, such as TNF-alpha, CRP, IL-6, IL-1Ra, Hb, and ferritin, are being measured at 10 days post administration or at the time of discharge, if earlier than 10 days. Anti-inflammatory and anti-oxidative activities are also being assessed. Clinical symptom improvement is determined using an 8-point sequence scale designed by the WHO. Quality of life, fatigue, and hospitalization periods are also evaluated. In pre-clinical studies, TADIOS (HX110) has shown to significantly inhibit lung damage in an acute lung injury mouse model. The therapeutic effects appeared to result from the control of excessive production of inflammatory and oxidative molecules such as TNF-a, IL-6, IL-1ß and ROS. The potential molecular mechanism underlying TADIOS' anti-inflammatory and anti-oxidative activities is its control of the Nrf2-HO-1 pathway. Thus, TADIOS appears to prevent or inhibit disease progression upon viral infection through a reduction of inflammatory and oxidative response. The results of these studies were published in the Journal of Ethnopharmacology.
Price Target Changed • Apr 16Price target decreased to ₩33,000Down from ₩48,697, the current price target is provided by 1 analyst. New target price is 29% above last closing price of ₩25,500. Stock is down 62% over the past year.
Is New 90 Day High Low • Feb 24New 90-day low: ₩24,550The company is down 16% from its price of ₩29,200 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
分析記事 • Feb 19Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize with...
お知らせ • Jan 23Helixmith Co., Ltd announced that it has received KRW 20 billion in fundingOn January 22, 2021, Helixmith Co., Ltd (KOSDAQ:A084990) closed the transaction.
お知らせ • Jan 22Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in fundingHelixmith Co., Ltd (KOSDAQ:A084990) announced a private placement of 4th series unregistered non-guaranteed private convertible bonds for gross proceeds of KRW 20,000,000,000 on January 20, 2021. The transaction will include participation from new investor, Japan-made New Bio Fund. The bond is issued at 0% coupon rate and will mature on January 22, 2026. The bonds are 100% converted into 657,527 common shares representing 1.92% stake at a fixed conversion price of KRW 30,417 per share. The conversion period is from January 22, 2022 to December 22, 2025. The transaction has been approved by the board of directors of the company. The subscription date is January 20, 2021 and payment date is January 22, 2021.
お知らせ • Dec 23Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion.Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,500,000 Price\Range: KRW 21500 Discount Per Security: KRW 322.5 Transaction Features: Rights Offering
Is New 90 Day High Low • Oct 16New 90-day low: ₩30,750The company is down 48% from its price of ₩58,800 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
お知らせ • Oct 06Helixmith to Be Deleted from Other OTCHelixmith Co., Ltd’s Ordinary Shares will be deleted from Other OTC effective September 29, 2020. The deletion is due to Inactive Security.
Is New 90 Day High Low • Sep 18New 90-day low: ₩41,800The company is down 35% from its price of ₩64,500 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.
